title: Inhibition of cardiac leptin expression after infarction reduces subsequent dysfunction.
abstract: Leptin is known to exert cardiodepressive effects and to induce left ventricular (LV) remodelling. Nevertheless, the autocrine and/or paracrine activities of this adipokine in the context of post-infarct dysfunction and remodelling have not yet been elucidated. Therefore, we have investigated the evolution of myocardial leptin expression following myocardial infarction (MI) and evaluated the consequences of specific cardiac leptin inhibition on subsequent LV dysfunction. Anaesthetized rats were subjected to temporary coronary occlusion. An antisense oligodesoxynucleotide (AS ODN) directed against leptin mRNA was injected intramyocardially along the border of the infarct 5 days after surgery. Cardiac morphometry and function were monitored by echocardiography over 11 weeks following MI. Production of myocardial leptin and pro-inflammatory cytokines interleukin (IL)-1β and IL-6 were assessed by ELISA. Our results show that (1) cardiac leptin level peaks 7 days after reperfused MI; (2) intramyocardial injection of leptin-AS ODN reduces early IL-1β and IL-6 overexpression and markedly protects contractile function. In conclusion, our findings demonstrate that cardiac leptin expression after MI could contribute to the evolution towards heart failure through autocrine and/or paracrine actions. The detrimental effect of leptin could be mediated by pro-inflammatory cytokines such as IL-1β and IL-6. Our data could constitute the basis of new therapeutic approaches aimed to improve post-MI outcome.
authors: Laboratoire TIMC-IMAG, UMR 5525 CNRS - University of Grenoble, Grenoble, France.
authors: C
authors: C
authors: Moro
authors: S
authors: S
authors: Grauzam
authors: O
authors: O
authors: Ormezzano
authors: M C
authors: MC
authors: Toufektsian
authors: S
authors: S
authors: Tanguy
authors: P
authors: P
authors: Calabrese
authors: J L
authors: JL
authors: Coll
authors: I
authors: I
authors: Bak
authors: B
authors: B
authors: Juhasz
authors: A
authors: A
authors: Tosaki
authors: J
authors: J
authors: de Leiris
authors: F
authors: F
authors: Boucher
mesh_terms: D000818:Animals; D016373:DNA, Antisense / Q000008:administration & dosage / Q000235:genetics; D004452:Echocardiography; D004797:Enzyme-Linked Immunosorbent Assay; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D020738:Leptin / Q000235:genetics / Q000378:metabolism*; D008297:Male; D009203:Myocardial Infarction / Q000378:metabolism* / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D018487:Ventricular Dysfunction, Left / Q000378:metabolism* / Q000503:physiopathology
chemical_list: D016373:DNA, Antisense; D053583:Interleukin-1beta; D015850:Interleukin-6; D020738:Leptin